sis in the context of clinical decision making can lead to poor care. Hospice is underutilized for patients with nonmalignant yet lifethreatening diseases. 1 Healthy older patients with good prognosis have low rates of cancer screening. 2 Older adults with advanced dementia or metastatic cancer are screened for slow-growing cancers that are unlikely to ever cause them symptoms but may lead to distress from false-positive results, invasive workups, and treatments. 3, 4 In recognition of these phenomena, guidelines increasingly incorporate life expectancy as a central factor in weighing the benefits and the burdens of tests and treatments (TABLE 1) . Prognostic indices offer a potential role for moving beyond arbitrary age-based cutoffs in clinical decision making for older adults. 2 However, little is known about the quality of prognostic indices for older adults, limiting their clinical use.
We performed a systematic review to describe the quality and limitations of validated non-disease-specific prognostic indices that predict absolute risk of all-cause mortality in older adults. Recognizing that older adults are more likely to have more than 1 chronic illness than younger adults, we focused on non-disease-specific indices.
METHODS
We used broad Medical Subject Heading terms (eg, mortality, prognosis, aged) to search MEDLINE, EMBASE, Cochrane, and Google Scholar from their inception through November 2011 for English-language-validated prognostic indices that predicted absolute risk of all-cause mortality in patients whose average age was 60 years or older. Authors of included studies and experts in the field were contacted and asked for additional published and unpublished sources. We excluded indices that estimated intensive care unit (ICU), in-hospital, or disease-specific mortality. Two investigators (L.C.Y. and A.K.S) independently applied these inclusion and exclusion criteria to select prognostic indices and independently abstracted their data. Disagreements were resolved by consensus or, if necessary, the involvement of a third investigator (S.J.L).
There are no accepted criteria to assess the quality of prognostic indices. Therefore, we adapted criteria from previous work published by experts in medicine and epidemiology. [28] [29] [30] [31] [32] [33] [34] [35] We abstracted data on the quality of prognostic indices, including information on potential bias, generalizability, and accuracy (TABLE 2) . For discrimination, we considered C statistics in the range of 0.50 to 0.59 to indicate poor, 0.60 to 0.69 to indicate moderate, 0.70 to 0.79 to indicate good, 0.80 to 0.89 to indicate very good, and 0.90 or greater to indicate excellent discrimination. 44 For calibration, we considered 10 or more percentage points' difference between predicted and observed mortality to be evidence of poor calibration and less than 10 percentage points' difference to be evidence that the model was well calibrated. To further assess the potential limitations of these indices in clinical practice, we tracked studies that predicted greater than 50% mortality, since 50% mortality represents the median residual lifespan. We report 95% confidence intervals on measures of discrimination and calibration where available.
RESULTS
One investigator title-screened 21 593 studies to identify 4120 potentially relevant abstracts (eFigure, available at http://www.jama.com). After excluding studies with participants whose average age was less than 60 years old; studies that predicted only relative risk; or indices that predicted only diseasespecific, in-hospital, or ICU mortality, there were 341 studies published between January 1987 and November 2011. After review of the full text of these studies, 317 studies were excluded, leaving 24 studies (eFigure). [36] [37] [38] [39] [40] [41] [42] [43] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] Three of these studies presented updated versions of an index, 36, 40, 53 and 5 provided additional validation for an index, 38, 43, 54, 58, 59 resulting in a total of 16 unique indices.
All indices were developed using secondary analysis of existing data sets of participants from the United States (11 indices)* and western Europe (4 indices). 42, 47, 48, 52 The most common final predictors of mortality included functional status and comorbidities (each only absent in Ͻ5 indices). Three indices tested only reproducibility and did not evaluate any form of transportability (split sample validation only 47, 48 and bootstrapping only 57 ) ( Table 2) . Only a single form of transportability was tested for 4 indices (geographic 39,46,52 and historical 51 ). For 4 indices, the investigators who developed the index tested the transportability of their index in a separate validation study. 37, 38, 42, 43, 49, 55, 58, 59 Two indices were additionally validated by an investigator not involved in the index's development. 36, 38, 41, 54 None of the examined indices had a C statistic Ն0.90; 3 indices had C statistics between 0.80 and 0.89, suggesting very good discrimination 39, 40, 49 ; 10 indices had C statistics between 0.70 and 0.79, suggesting good discrimination † ; and 3 indices had C statistics between 0.60 and 0.69, suggesting moderate discrimination. 45, 47, 51 Indices were generally well calibrated across risk groups (TABLE 3) . Two indices reported a greater than 10% difference between predicted and observed mortality. 36, 40 We present a descriptive summary of each index by setting. Results of data abstraction regarding potential bias, generalizability, and accuracy are shown in Table 3 and TABLE 4 
Community-Dwelling Older Adults
Our review identified 6 indices for community-dwelling older adults. Indices estimated mortality risk from 1 year 56 to 5 years. 55 The highest-risk group from Schonberg et al at 9-year follow-up predicted 92% mortality (95% CI, 86%-96%). 58 Gagne et al 56 The index is accurate in patients who were not included in the development cohort but who are from the same underlying population; a measure of overfitting (matching the predictive model to random noise in the data)
Data resampling (also called bootstrapping) d
Transportability
The index is accurate in patients drawn from a different but related population or in data collected by using methods that differ from those used in development; a measure of both overfitting and underfitting (the omission of important predictors of mortality)
Nonrandomly split sample e or independent validation Methodological Accuracy is maintained when the index is tested in data collected using different methods; independent validation tests the accuracy of the index by investigators not involved in the development of the index 28 Hayden et al, 34 McGinn et al, 35 and Steyerberg et al. 29 b Higher values closest to 1 indicate better fit. c Higher values closest to 1 indicate better discrimination. d Develop the index in the entire data set, and then validate it in multiple bootstrap samples generated from the original sample with replacement. e Develop the index in one part of the data and validate it in another portion that differs on some major variable. Nonrandomly split samples measure an index's transportability better than randomly split samples. midwestern United States (n = 1667). The index was well calibrated but showed only moderate discrimination. Accuracy was similar for 1-year mortality. Lee et al 39 developed a 4-year mortality index in community-dwelling adults older than 50 years from the eastern, western, and central United States who were interviewed in the Health and Retirement Survey of 1998 (81% participation rate, n=11 701). To test geographic transportability, the index was validated in interviewees from the southern United States (n=8009). The Lee et al index was well calibrated and showed very good discrimination.
The index by Schonberg et al 55 to predict 5-year mortality was developed from a nationally representative sample of adults older than 65 years (n = 16 077) who responded to the 1997-2000 National Health Interview Survey (NHIS) (74% participation rate); it was well calibrated and had good discrimination in a random sample of n = 8038 adults drawn from the same data source. Schonberg et al 58 then further validated the index in respond e n t s t o t h e 2 0 0 1 -2 0 0 4 N H I S (n = 22 057, 25% aged Ͼ80 years, 57% female, 12% dependent in at least 1 instrumental activity of daily living, 18% with diabetes, 15% with cancer) and found no change in discrimination (C statistic, 0.75). The KaplanMeier method demonstrated widening separation between risk groups out to 9 years.
Nursing Home Residents
Two indices were developed for the nursing home, both using the Minimum Data Set (MDS), a clinical and administrative data set that is federally required of all US nursing homes. The MDS Mortality Rating Index by Porock et al 37 to estimate 6-month mortality in nursing home patients was developed using data from all Missouri long-term care residents in 1999. Study authors later created a simplified version of this model using the same data set. 53 The revised Flacker and Kiely 36, 50 long-stay index for 1-year mortality was developed and validated from the MDS using a split sample of nursing home residents who were 65 years and older and residing longer than 1 year in The "Silver Code" by Di Bari et al, 47 a 1-year index for emergency triage of individuals aged 75 years and older, was developed and validated using administrative records of patients admitted to the hospital via the emergency department from Florence, Italy, in 2005 (n = 10 913). They achieved 91% linkage across 4 administrative data sets (demographics, hospitalizations, prescription medications, and mortality). Random split sample validation was conducted on half the cohort. The index was well calibrated and discriminatory ability was moderate.
Fischer et al 49 conducted a retrospective medical record review to develop a 1-year index for hospitalized elderly individuals using 4 prespecified predictors called the CARING criteria, collected at admission. Their sample included patients admitted to the medical service of a US Department of Veterans Affairs hospital in a 4-month period in 1999 (n=873). Participants admitted in the first 2 months of the study period were included in the development cohort; the remainder were in the validation cohort. The model had very good discrimination and a reported error rate of 0.26 in the validation cohort. Youngwerth et al 59 later prospectively tested the external validity of the CARING criteria in a younger, sexbalanced sample from a university hospital in 2005 (n= 427, average age 54 years, 50% female). No C statistic was reported for the external validation.
The Burden of Illness Score for Elderly Persons by Inouye et al 40 updated previous indices developed by the same group 60, 66 by adding functional and laboratory data to diagnoses from administrative data to estimate 1-year mortality. Participants were drawn from a prospective study of individuals aged 70 years and older who were hospitalized at Yale-New Haven Hospital from 1989 through 1991 (n=525). The study was validated in a sample of 1246 participants from 27 Connecticut hospitals who were 65 years and older with a principal discharge diagnosis of pneumonia from 1995 through 1996. The investigators demonstrated improvement in the C statistic with the addition of laboratory and functional and cognitive measures to administrative data (validation C statistics, administrative alone, 0.59; all measures, 0.77). The model was well calibrated at the extremes but was less accurate in middlerisk groups (Table 4) .
Pilotto et al 42 mogram is convenient in that it predicts multiple end points from a single score. The index includes the APACHE III scale, which requires arterial blood gas measurement.
Levine et al 51 developed a 1-year prognostic model for hospitalized elderly individuals after discharge using data from a cohort of patients admitted to hospitalist and nonhospitalist physicians at the University of Chicago Hospitals from July 1997 through June 1999 (development cohort, n=2739) and July 1999 through June 2001 (validation cohort, n=3643). The index had moderate discriminatory ability and was well calibrated.
Walter et al 41 developed a 1-year index for elderly individuals after hospital discharge using secondary data from a study of patients aged 70 years and older who were hospitalized between 1993 and 1997 at the University of Hospitals Cleveland (development cohort, n=1495) and the Akron City Hospital (validation cohort, n=1427). The model demonstrated good discrimination and was well calibrated across risk groups. Rozzini et al 54 subsequently externally validated the index's performance predicting 6-month mortality in a retrospective analysis of 840 consecu- tively admitted participants to a hospital in Italy and found monotonic increases in mortality for each predicted risk level (observed 4%, 10%, 25%, and 46% 6-month mortality).
The Dramé et al 48 index for 2-year mortality was developed in hospitalized adults aged 75 years and older based on secondary data obtained in the emergency department as part of the SAFES study in France (n = 870). It showed good calibration and discrimination in a split sample validation of 436 older adults.
COMMENT
Our review identified 16 validated nondisease-specific prognostic indices for older adults. Studies were abstracted for information about index quality, including potential for bias, generalizability, and accuracy.
We highlighted criteria for evaluating prognostic indices and identified several high-quality prognostic indices. Unfortunately, although these indices hold the promise of improving the targeting of interventions in older adults, there is insufficient evidence at this time to recommend the widespread use of prognostic indices in clinical practice. Only 2 indices were validated by investigators not involved in the studies' development, and no index had been prospectively tested and found to be accurate in a large diverse sample. Confidence intervals were not presented for either measures of discrimination or calibration for 14 indices. By our measures, no study was completely free from potential sources of bias. Testing of transportability was limited, raising concerns about overfitting and underfitting. These factors limit a clinician's ability to assess the accuracy of these indices across patient groups that differ according to severity of illness, methodology of data collection, geographic location, and time.
Even if quality barriers are overcome, important limitations remain. Several indices require collection of information that may not be routinely assessed in elderly patients, such as activities of daily living. Many of these indices rely on clinical information from administrative data sets, and the accuracy of codes from the International Classification of Diseases, Ninth Revision, has been called into question. 61 Thus, indices by Gagne et al, Inouye et al, and Levine et al may be better suited to risk adjustment than clinical use. Moreover, coding algorithms are subject to change. The MDS has been updated to a new version (3.0) since the development of indices for nursing home patients, and some variables in indices by Porock et al and Flacker and Kiely have been changed or are no longer present. 67 Finally, PubMed has no single Medical Subject Heading term for prognostic index, making it difficult for a busy clinician to locate these studies.
Ultimately, an index will be judged not only on its accuracy across diverse settings, but also on its clinical effect. Studies that demonstrate effect on prognostic estimates, clinician behavior, and patient outcomes have a higher level of evidence for use in clinical decision making (eg, Ottawa ankle rules). 35 We are aware of only 2 small studies that tested the effect of these indices on clinical outcomes. 51, 68 The highest level of evidence, however, would come from large prospective trials that randomize clinicians to using the index or not, evaluating the effect of the index on prognostic estimates, clinical decision making, and patient outcomes. Such large randomized trials have not been performed.
None of the C statistics for the included indices were higher than 0.90, suggesting unexplained variation in mortality. However, discriminatory ability of these indices is consistent with other indices that commonly drive clinical decisions, such as the CHADS2 index to help determine warfarin therapy (C statistic, 0.68-0.72) 69 ; the Framingham risk score to help determine lipid therapy (C statistic, 0.63-0.83) 70 ; and the TIMI risk score to help determine invasive therapy for unstable angina (C statistic, 0.65). 71 There may be a limited role for the highest-quality indices in the right settings. If patient characteristics align closely with those of the development or validation cohorts, clinicians may find prognostic information useful to help inform, though not replace, their clinical judgment. Prediction rules have been shown to outperform clinicians in terms of prognostication, 72, 73 whereas human prediction on its own is fraught with bias. 74 The indices we identified were developed from heterogeneous groups of patients. Applying this information to the individual patient, therefore, requires a nuanced use of the index. Patients are likely to have conditions that are not included in the index (eg, Parkinson disease). The clinician must account for these conditions and decide whether their effect is adequately accounted for by the indices' predictors.
Indices are most likely to be clinically useful when they predict a wide range of mortality. Clinical decisions are most likely to be influenced by either very low or very high mortality risk. Although 10 indices predicted greater than 50% mortality, only 3 predicted greater than 80% risk in the highest risk group. Midrange probabilities may still be useful in clinical decisions in which life expectancy plays a role, allowing patient preferences to drive the physician's recommendation. The following case illustrates this issue.
Case
Ms A is a 75-year-old clinic patient who has been hospitalized twice in the past year for chronic obstructive pulmonary disease and has a history of diabetes and difficulty walking a quarter mile. She has not been previously screened for colon cancer. The US Preventive Services Task Force recommends that individual factors should determine the decision to screen or not screen patients aged 75 to 85 years; patients must live at least 7 years to benefit from screening, and the net benefits in this age group are small. 16 Using indices developed for communitydwelling elderly individuals, it is determined that Ms A has a 54% to 67% mortality risk at 4 years (Lee et al in-dex) and 75% at 9 years (Schonberg et al index). Should Ms A undergo colorectal cancer screening?
In this case, the prognostic information may be helpful as her physician discusses the possibility of colon cancer screening in relation to other health priorities, such as maintaining mobility. Because her median life expectancy is less than 4 years, Ms A will probably not live long enough to benefit from screening. And if screening is difficult for her, there is enough uncertainty in her likelihood of benefit that she probably should focus on other priorities. However, if she feels strongly about wanting to be screened, the estimates are not strong enough on their own to refute that decision.
Limitations
We have refrained from explicitly ranking or categorizing the quality of these indices, recognizing that no agreed-on scientifically developed system for rating index quality currently exists. Some will argue that minimizing risk for potential bias is of critical importance, while others might argue that an index should be judged on its ability to perform accurately across diverse settings. Our review excluded indices that estimated only relative risk or had not been validated, and future research may find that some of these indices are generalizable and accurate. Our ability to assess publication bias was limited by our small sample size.
CONCLUSION
While neither a clinician nor an index can predict with absolute certainty how long an older adult will live, validated prognostic indices might improve the accuracy of the prognostic assumptions that influence clinical decisions. However, further research is needed before general prognostic indices for elderly individuals can be recommended for routine use. Future research should focus on prospectively testing the validity of these indices across diverse clinical settings and analyzing their effect on clinical decision making and patient outcomes.
